Transinsight and antibodies-online Develop Software for Semantic Gene and Protein Identification

Since July 2009 Transinsight GmbH and antibodies-online GmbH partner together with TU Dresden and RESprotect GmbH to develop and deploy new semantic search technologies for the Life-Science industry. Their joint efforts are funded by the THESEUS research program from the German Federal Ministry of Economics and Technology (BMWi). With only a few months into the project, the partnering companies are now able to demonstrate a first outcome of their research to the public: Research antibodies that semantically fit to genes and proteins discussed within a certain biomedical publication are automatically suggested to the reader on Transinsight's search engine www.GoPubMed.com.

"The scientist, who keeps himself up-to-date on recent biomedical publications with our knowledge-based search engine GoPubMed.com is now further supported by suggestions of semantically fitting research products for his/her specific research needs," says Dr. Michael R. Alvers, founder and CEO of Transinsight GmbH. The time consuming search for the right research antibody to a specific research question is one of the key pains in proteomics and genomics laboratories. Any simplification of this search problem, which delivers correct information instead of unhelpful, generic advertising, is welcome within the scientific community. Searching, finding and ordering the right research antibody from within a global offer of 500.000 products from more than 500 suppliers worldwide is normally a tedious work. To apply semantic, knowledge driven product recommendations to biomedical publications and thus to allow to significantly reduce the workload for the scientist always in need of research products is a truly innovative approach.

"Once the scientist has chosen a product of interest, antibodies-online GmbH takes care of all the rest, i.e. procurement of the desired products from anywhere around the world," adds Dr. Andreas Kessell, founder and managing director of antibodies-online GmbH. "Our customer is not bound to the portfolio of a single supplier but can chose from a neutral portfolio of research antibodies, that are suggested with the biomedical publications," says Dr. Kessell.

The software solution behind this innovative offer of the partnering companies Transinsight und antibodies-online is currently being developed within the THESEUS research program. Transinsight's existing semantic search platform already detects genes and proteins reliably in scientific publications and these results can be linked to the products on antibodies-online.com. "With the launch of this first prototype we managed the initial integration of the information provided on the two platforms of the partnering companies - however, the list of tasks to be taken on remains long," explains Dr. Alvers.

About antibodies-online GmbH
With more than 200.000 research antibodies offered antibodies-online GmbH is one of the leading internet marketplaces for research products worldwide. The scientific community apparently searches the internet for products that suit their research needs. On antibodies-online's websites scientists can search or browse the offer of numerous suppliers worldwide as well as order the antibody directly online, via phone or via fax. The company was founded as a spin-off of Aachen Technology University and the University Hospital of Aachen as a supplier independent German platform in April 2006. By the end of 2008 anticorps-enligne.fr, kangti-zaixian.cn and antibodies-online.com were launched as international marketplaces. Since then all listed antibodies are marketed and distributed worldwide.

About Transinsight GmbH
Transinsight develops knowledge-based semantic solutions in the Life Sciences. Their flagship products www.Go3R.org and www.GoPubMed.com, renowned biomedical search engines, are the first knowledge-based search systems of the next generation not only for the Life Sciences on the internet. In acknowledgement of the technologies developed by the company, Transinsight has repeatedly been honored with international awards i.e. the reddot design award best of the best 2009 and the German Industry Prize 2010. The firm works in close collaboration with the Dresden University of Technology. Selected customers are: Unilever, BASF, BfR, Statoil, RWE, Abcam und EMBL. For further information on Transinsight on the internet, see www.transinsight.com.

About THESEUS research program
The THESEUS research program was launched by the Federal Ministry of Economics and Technology (BMWi) in 2007 as a flagship project of the German Federal Government. As part of the program, about 60 companies, research institutes and universities are running projects to develop application-orientated basic technologies and technical standards for the internet of services. The aim is to develop new products and services for the internet. The program is scheduled to run for five years and is funded by around €100 m from the BMWi. The funds made available for research and development are being divided equally between science and economics. An additional €100 m is being contributed by interested partners in industry and research from their own funds.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...